VYNE
NASDAQVYNE Therapeutics Inc.
Price$0.64+0.04 (+6.55%)
2026-03-092026-06-10
News · 26 weeks260%
2025-12-142026-06-07
Mix1190d
- SEC Filings5(45%)
- Insider5(45%)
- Other1(9%)
Latest news
25 items- SECAmendment: SEC Form S-4/A filed by VYNE Therapeutics Inc.S-4/A - VYNE Therapeutics Inc. (0001566044) (Filer)
- INSIDERPRESIDENT AND CEO Domzalski David was granted 30,791 shares, increasing direct ownership by 8% to 438,779 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form SCHEDULE 13G filed by VYNE Therapeutics Inc.SCHEDULE 13G - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECSEC Form 10-Q filed by VYNE Therapeutics Inc.10-Q - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECAmendment: SEC Form S-4/A filed by VYNE Therapeutics Inc.S-4/A - VYNE Therapeutics Inc. (0001566044) (Filer)
- INSIDERSEC Form 4 filed by Zeronda Tyler4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Stuart Iain4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Harsch Mutya4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Domzalski David4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- SECSEC Form S-4 filed by VYNE Therapeutics Inc.S-4 - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 8-K filed by VYNE Therapeutics Inc.8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 10-K filed by VYNE Therapeutics Inc.10-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- SECSEC Form 425 filed by VYNE Therapeutics Inc.425 - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- INSIDERPRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,684 shares, decreasing direct ownership by 3% to 416,208 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,448 shares, decreasing direct ownership by 2% to 115,239 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 7,858 shares, decreasing direct ownership by 7% to 103,795 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERCHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 3,579 shares, decreasing direct ownership by 3% to 125,905 units (SEC Form 4)4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- SECSEC Form 425 filed by VYNE Therapeutics Inc.425 - VYNE Therapeutics Inc. (0001566044) (Subject)
- SECVYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - VYNE Therapeutics Inc. (0001566044) (Filer)
- PRVYNE Therapeutics and Yarrow Bioscience Announce Merger AgreementFollowing closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to
- INSIDERSEC Form 4 filed by Director Barbari Sharon4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Basta Steven L4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
- INSIDERSEC Form 4 filed by Director Little Elisabeth Sandoval4 - VYNE Therapeutics Inc. (0001566044) (Issuer)
VYNE FAQ
7 questionsWhat does VYNE Therapeutics Inc. do?
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib...Where does VYNE stock trade?
VYNE Therapeutics Inc. (VYNE) is listed on NASDAQ.What sector and industry is VYNE in?
VYNE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did VYNE Therapeutics Inc. go public?
VYNE Therapeutics Inc. (VYNE) completed its IPO in 2018.What are analysts saying about VYNE?
VYNE Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from BTIG Research: Neutral on 2025-07-31. Recent price targets range from $700.00 to $800.00.What companies are similar to VYNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VYNE side-by-side with any of them on Quantisnow.How can I track VYNE on Quantisnow?
Quantisnow aggregates VYNE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VYNE to receive live email and push alerts on every new disclosure.